Pulmonary lymphoma, a rare form of cancer originating in the lungs, involves the proliferation of malignant lymphocytes. Cancer research has been pivotal in enhancing our understanding of this disease, particularly its subtypes such as primary pulmonary lymphoma and secondary involvement of the lungs by systemic lymphoma. Advances in molecular biology and immunohistochemistry have improved diagnostic accuracy, enabling differentiation from other lung malignancies and infections. Research has also explored targeted therapies, including monoclonal antibodies and kinase inhibitors, offering new hope for treatment beyond conventional chemotherapy and radiotherapy. Ongoing clinical trials and genomic studies are crucial, aiming to uncover specific genetic mutations and immune profiles that can be targeted to personalize treatment strategies and improve patient outcomes.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China